Waltham, MA, United States of America

Kevin Paul Foley

USPTO Granted Patents = 32 

 

Average Co-Inventor Count = 4.1

ph-index = 16

Forward Citations = 578(Granted Patents)


Location History:

  • Waltham, MA (US) (2009 - 2015)
  • Cambridge, MA (US) (2010 - 2015)
  • Landsdale, PA (US) (2014 - 2015)

Company Filing History:


Years Active: 2009-2015

Loading Chart...
Loading Chart...
32 patents (USPTO):Explore Patents

Title: Innovations in Cancer Therapy by Kevin Paul Foley

Introduction

Kevin Paul Foley, an accomplished inventor based in Waltham, MA, has made significant contributions to the field of oncology through his patents. With a total of 32 patents to his name, he has consistently demonstrated a commitment to advancing cancer treatment methods.

Latest Patents

Foley’s latest innovations include groundbreaking work on cancer therapy using a combination of Hsp90 inhibitory compounds and an EGFR inhibitor. This patent outlines a pharmaceutical combination that includes these inhibitors, providing a method for treating proliferative disorders in patients. Additionally, he developed triazole compounds that modulate Hsp90 activity, which are crucial for preventing or treating hyperproliferative disorders like cancer.

Career Highlights

Currently, Foley is associated with Synta Pharmaceuticals Corporation, a key player in the development of new cancer therapies. His extensive work in the pharmaceutical industry has positioned him as a leading inventor in the quest for effective cancer treatments.

Collaborations

In his journey, Foley has collaborated with esteemed colleagues such as Zhenjian Du and Weiwen Ying. These partnerships have undoubtedly contributed to the innovative breakthroughs that Foley has achieved in his research and patent applications.

Conclusion

Kevin Paul Foley continues to be a pivotal figure in the development of novel cancer therapies through his inventive spirit and collaborative efforts. His dedication to innovation is reflected in his numerous patents aimed at improving treatment options for patients facing hyperproliferative disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…